On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridaySep 29, 2017 12:52 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event

Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins Growing portfolio of intellectual property includes 19 patents filed across 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is…

Continue Reading

ThursdaySep 28, 2017 2:05 pm

Global Payout, Inc. (GOHE) CEO Discusses Innovative FINTECH Company’s Past, Present and Future

Innovative Global Reserve Platform enables seamless international payments “Banking in a box” Global Reserve Platform provides full front-to-back office processing for banks Solutions serve the global logistics industry, high-risk sectors and more In a recent interview (http://cnw.fm/1rsK8) with NetworkNewsWire, Global Payout, Inc. (OTC: GOHE) CEO James Hancock detailed where the innovative payment solutions company has been, where it is now, and where it plans to be in the future. Global Payout is a frontrunner in the FINTECH revolution (http://cnw.fm/F2sRA), offering versatile and innovative solutions for domestic and international organizations distributing money on a global scale. The company’s solutions include a…

Continue Reading

WednesdaySep 27, 2017 3:51 pm

EVIO, Inc. (SGBYD) Changes Name, Adopts New Ticker Symbol and Announces a Reverse Stock Split

Name change to EVIO, Inc., from Signal Bay, Inc., reflects fact that EVIO Labs division generates majority of company volume New ticker symbol of EVIO will become effective October 3, 2017, for the legalized cannabis industry’s quality control testing and ancillary advisory services company Reverse stock split is positioned to attract institutional investors to provide funding for company’s vision of becoming a leading biotechnology firm in the cannabis industry EVIO, Inc. (OTCQB: SGBYD) has changed its name from Signal Bay, Inc. and also announced a reverse stock split (http://cnw.fm/Vk8tC). The life science company will also have a new ticker symbol,…

Continue Reading

WednesdaySep 27, 2017 3:19 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies

Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has…

Continue Reading

WednesdaySep 27, 2017 1:14 pm

Grey Cloak Tech Inc. (GRCK) Signs Letter of Intent to Acquire Eqova Life Sciences

Clinical-grade full spectrum hemp oil products created for licensed medical practitioners included Science-backed education, superior products meet requirements of medical profession Medical cannabinoid product revenue projected to reach $1.15 billion by 2020 Grey Cloak Tech Inc. (OTC: GRCK) recently announced that it has signed a binding Letter of Intent to purchase Eqova Life Sciences, a Colorado-based medically-focused company producing clinical-grade full spectrum hemp oil products. To date, no other hemp oil company has exclusively focused on the medical practitioner market, leaving this important segment largely underserved. Grey Cloak Tech, which is known for its click fraud prevention products, has been…

Continue Reading

MondaySep 25, 2017 3:46 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Attains $43M in Capital, Plans Significant Production Capacity Increase

Aaron Keay, CEO, says plans set for greater production capacity and strategy for global distribution in emerging markets Expansion of ABcann’s Vanluven facility underway, along with construction of the company’s 150,000 sq. ft. Kimmett facility Napanee, Ontario-based firm uses proprietary plant-growing technology and is pursuing opportunities in Australia and Germany ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017, it announced on August 29 (http://cnw.fm/1BXpf). ABcann manufactures and distributes medical cannabis under a license issued by Health Canada to…

Continue Reading

MondaySep 25, 2017 1:45 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets

Technology that improves bio-absorption and bio-availability Bioactive compound delivery system with application across a range of drugs Revenue streams from out-licensing The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB:…

Continue Reading

FridaySep 22, 2017 12:01 pm

For ChineseInvestors.com, Inc. (CIIX) Beauty is more than Just Skin Deep

Entering largely untapped Chinese CBD skin care market Health benefits widely recognized Vibrant online marketing campaigns underway Chinese women, it will be no surprise to learn, are as beauty conscious as their sisters in other countries. For centuries, they have employed a variety of cosmetic embellishments to enhance social status and, perhaps, catch someone’s eye. Lip coloring has been in vogue for at least 1,000 years, and, at some point, the application of powdered rice to lighten skin tone became fashionable. But beauty is more than skin deep, which is perhaps why ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a line…

Continue Reading

ThursdaySep 21, 2017 4:10 pm

Algae Dynamics Corp. (ADYNF) Collaborates with University of Western Ontario

Research finds that higher levels of the brain chemical GABA can reverse negative effects such as schizophrenia and depression Professor Steven Laviolette, who spearheaded the study, hopes that GABA-increasing cannabinoid compounds developed with industrial partners from this research could lead to clinical trials “in the next few years” Algae Dynamics Corp. has signed a collaborative agreement with the University of Western Ontario, giving the company the patent rights to any drugs developed as a result of research Algae Dynamics Corp. (OTCQB: ADYNF) is in a collaboration agreement with the University of Western Ontario (now rebranded as Western University), which is…

Continue Reading

ThursdaySep 21, 2017 3:00 pm

India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials

Four drug candidates in the pipeline Potential sales of Alzheimer’s drugs run to billions Hyalolex heading for clinical trials India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease. Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has…

Continue Reading

Contact us: 303.498.7722